Alpha-Pinene
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Bicyclic monoterpene |
| Molecular Formula / CAS | C₁₀H₁₆ · CAS 80-56-8 |
| Primary Botanical Source(s) | Frankincense / Boswellia serrata oleoresin, pine, rosemary, juniper, cardamom, nutmeg/mace |
| Plant Part | Oleoresin (frankincense); needle/leaf oil (pine, rosemary); berry (juniper); seed (cardamom) |
| Typical Content | A major monoterpene of Boswellia oleoresin essential oil, reported in the range of roughly 10–70% depending on species and chemotype |
| Solubility / Format | Volatile, lipophilic monoterpene; carried in oil-soluble and essential-oil-type extract formats |
| Sourcing Status | Product-live — genuine match via Herbuno’s frankincense oil-soluble extract line |
| Buy from Herbuno | Indian Frankincense Oil Soluble Extract |
Name origin: Alpha-pinene takes its name from the pine genus, Pinus, in whose resin and needle oil it was first characterised as a defining constituent, though it is now recognised as one of the most widely distributed monoterpenes in the plant kingdom, found across hundreds of aromatic species well beyond conifers. Traditional use: Resinous alpha-pinene-rich material has an extensive independent traditional-use history through frankincense (Boswellia oleoresin), burned as incense and used medicinally across Middle Eastern, North African and South Asian traditions for millennia, predating any chemical understanding of its monoterpene composition; pine, rosemary and juniper each carry parallel, separate traditional respiratory and topical-use histories. Research trajectory: Alpha-pinene research began with basic essential-oil chemical characterisation and has expanded substantially into anti-inflammatory, antimicrobial and organ-protective pharmacology over the past two decades, with particular research attention on its distinct activity relative to its structural isomer beta-pinene — the two compounds frequently show different, and sometimes opposite, potency in the same assay. Commercial source: Frankincense (Boswellia serrata) oleoresin is a well-documented major source of alpha-pinene, distinct from the boswellic-acid-standardised triterpene fraction that most commercial Boswellia extracts target.
Evidence for Alpha-Pinene Applications
Alpha-pinene is one of the most abundant monoterpenes in nature, accounting for more than half of global monoterpene emissions from vegetation, and is a major volatile constituent of frankincense oleoresin specifically — GC-MS analyses across Boswellia species and chemotypes have reported alpha-pinene content ranging from roughly 10% to over 70% of total essential oil composition, making it, alongside alpha-thujene, one of the two dominant monoterpenes of most frankincense chemotypes (et al. 2021). Claim strength: Moderate.
In LPS-stimulated mouse peritoneal macrophages, alpha-pinene treatment significantly reduced production of the inflammatory mediators IL-6, TNF-alpha and nitric oxide, and inhibited inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression through suppression of both MAPK and NF-κB signalling pathways — a mechanistic profile consistent with a genuine anti-inflammatory action rather than a nonspecific cytotoxic effect (Kim et al. 2015). Claim strength: Moderate.
A structure-activity study comparing pinene isomers and enantiomers in human chondrocytes found that (+)-alpha-pinene produced the most potent inhibition of IL-1beta-induced inflammatory and cartilage-degrading (catabolic) pathways — including NF-κB and JNK activation and expression of iNOS and the matrix metalloproteinases MMP-1 and MMP-13 — while (-)-alpha-pinene was less active and beta-pinene was inactive in the same assay, positioning (+)-alpha-pinene specifically as the most promising candidate for further anti-osteoarthritic research among the pinene isomers tested (Rufino et al. 2015). Claim strength: Moderate.
Rodent studies have extended alpha-pinene’s anti-inflammatory and antioxidant profile to organ protection, including reduced liver fibrosis markers via suppression of oxidative stress and the TGF-beta/Smad3 signalling pathway in a carbon-tetrachloride liver-injury model, and reduced oxidative and inflammatory markers in kidney and testicular tissue in a comparable injury model. These findings come from animal-model research using injected or high-dose exposure and have not been evaluated in human subjects or with oral supplementation. Claim strength: Emerging.
A broader review cataloguing pinene pharmacology reports additional documented activities including antimicrobial, anticoagulant, antitumor, antimalarial and antioxidant effects, alongside early work on pinene’s odour-exposure effects on stress tolerance via inhalation pathways rather than ingestion (et al. 2021). Because alpha-pinene is volatile and readily absorbed by inhalation, its pharmacology has been studied through both oral/injected and inhalation exposure routes, which formulators should distinguish when evaluating relevance to a specific finished-product format. Claim strength: Moderate.
Dosage & Formulator Specification
No alpha-pinene-standardised commercial ingredient with an established human oral dosing range exists; published pharmacological research has used cell-culture concentrations in the low µM-to-mM range and rodent doses in the tens of mg/kg range, alongside separate inhalation-exposure research at low ambient concentrations, none of which directly establishes an oral supplemental dose.
Analytical quantification of alpha-pinene in frankincense or other essential-oil-type material is performed by GC-MS, the standard method for volatile monoterpene profiling; because alpha-pinene, beta-pinene and alpha-thujene frequently co-occur and their relative proportions vary substantially by Boswellia species and chemotype, formulators should request a full monoterpene GC-MS profile rather than an alpha-pinene figure in isolation.
Given alpha-pinene’s volatility, oil-soluble and essential-oil-type extract formats preserve it more effectively than aqueous or powder-based extraction, which concentrate the non-volatile triterpene (boswellic acid) fraction instead. Formulators should also account for evaporative loss during any heat-processing or open-air manufacturing step, since alpha-pinene is readily lost to volatilisation under warm or prolonged-exposure conditions.
Regulatory positioning for alpha-pinene follows established frankincense, pine and rosemary essential-oil precedent; it is a GRAS-recognised flavouring substance in food contexts and a common constituent of FEMA- and IFRA-regulated fragrance and flavour materials. No alpha-pinene-specific supplement dosing limit exists; formulators making anti-inflammatory or chondroprotective claims should note that most supporting evidence comes from isolated-compound cell and animal studies rather than from finished frankincense-extract clinical trials measuring alpha-pinene exposure directly.
Frequently Asked Questions — Alpha-Pinene
No. Boswellic acids are non-volatile triterpene compounds and are the standardisation marker for most commercial Boswellia serrata supplements, including Herbuno’s Boswellic Acids and AKBA powder lines. Alpha-pinene is a separate, volatile monoterpene fraction of frankincense oleoresin, better captured in an oil-soluble extract format.
Although structurally very similar, research has found meaningful potency differences between the two isomers in specific assays — for example, one chondroprotective study found (+)-alpha-pinene was the most active anti-inflammatory compound tested while beta-pinene was inactive in the same model, so the two should not be assumed pharmacologically interchangeable.
Alpha-pinene content varies by Boswellia species and chemotype, with some populations of B. sacra and B. dalzielii reported at 60–70%+ of essential oil composition. Because it is volatile, oil-soluble extraction formats capture it more effectively than aqueous or standardised powder extracts, which target the non-volatile boswellic acid fraction instead.
Cell studies have shown alpha-pinene suppresses key inflammatory signalling pathways (NF-κB and MAPK) and reduces production of inflammatory cytokines in macrophage and chondrocyte models. Animal studies have extended this to liver, kidney and testicular protection. Human clinical trial data specific to alpha-pinene is not yet available.
Related compounds: Beta-Pinene, Boswellic Acid